Stocks In Focus: ResMed, March 18 2026

Key Takeaways

• •

  Resilience against GLP-1 headwinds - While weight-loss drugs were feared to be an existential threat, data suggests they are often complementary to sleep apnea therapy rather than a total replacement.

  “The market overreacted to the GLP-1 threat, forgetting that a more health-conscious population actually leads to higher diagnosis rates, not lower device demand.”

• •

  Dominance through competitor defaults - ResMed continues to entrench its market leadership as it capitalizes on the prolonged product recall struggles of its primary rival, Philips.

• •

  Shift to high-margin recurring revenue - The investment thesis is evolving from hardware sales to a digital-first model focused on patient monitoring software and consistent mask replacement cycles.

  “The market overreacted to the GLP-1 threat, forgetting that a more health-conscious population actually leads to higher diagnosis rates, not lower device demand.”

Episode Description

This week, Scott talks to Motley Fool Director of Research, Ryan Newman, about medical device maker, ResMed (ASX:RMD).See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.